1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians. 2021;71(1):7–33. DOI: 10.3322/caac.21654
2. Ahmed T, Marmagkiolis K, Ploch M, Irizarry-Caro JA, Amatullah A, Desai S et al. The Year in Cardio-oncology 2022. Current Problems in Cardiology. 2023;48(1):101435. DOI: 10.1016/j.cpcardi-ol.2022.101435
3. Essa H, Dobson R, Wright D, Lip GYH. Hypertension management in cardio-oncology. Journal of Human Hypertension. 2020;34(10):673– 81. DOI: 10.1038/s41371-020-0391-8
4. Chang H-M, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1. Journal of the American College of Cardiology. 2017;70(20):2536–51. DOI: 10.1016/j.jacc.2017.09.1096
5. Totzeck M, Schuler M, Stuschke M, Heusch G, Rassaf T. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. International Journal of Cardiology. 2019;280:163–75. DOI: 10.1016/j.ijcard.2019.01.038
6. Cohen JB, Brown NJ, Brown S-A, Dent S, Van Dorst DCH, Herrmann SM et al. Cancer Therapy–Related Hypertension: A Scientific Statement From the American Heart Association. Hypertension. 2023;80(3):e46–57. DOI: 10.1161/HYP.0000000000000224
7. Van Dorst DCH, Dobbin SJH, Neves KB, Herrmann J, Herrmann SM, Versmissen J et al. Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients. Circulation Research. 2021;128(7):1040–61. DOI: 10.1161/CIRCRESAHA.121.318051
8. Osumi H, Shinozaki E, Ooki A, Wakatsuki T, Kamiimabeppu D, Sato T et al. Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second‐line chemotherapy. Cancer Medicine. 2021;10(2):615–25. DOI: 10.1002/cam4.3638
9. Zhong J, Ali AN, Voloschin AD, Liu Y, Curran WJ, Crocker IR et al. Bevacizumab‐induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab. Cancer. 2015;121(9):1456–62. DOI: 10.1002/cncr.29234
10. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J et al. 2022 ESC Guidelines on cardiooncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). European Heart Journal. 2022;43(41):4229–361. DOI: 10.1093/eurheartj/ehac244
11. Васюк Ю.А., Гендлин Г.Е., Емелина Е.И., Шупенина Е.Ю., Баллюзек М.Ф., Баринова И.В. и др. Согласованное мнение Российских экспертов по профилактике, диагностике и лечению сердечно-сосудистой токсичности противоопухолевой терапии. Российский кардиологический журнал. 2021;26(9):152-233. DOI: 10.15829/1560-4071-2021-4703
12. Чазова И.Е., Агеев Ф.Т., Виценя М.В. Сердечно-сосудистые осложнения противоопухолевой терапии. - М.: ГРАНАТ, 2019. – 160с. ISBN 978-5-906456-44-1
13. Hageman S, Pennells L, Ojeda F, Kaptoge S, Kuulasmaa K, De Vries T et al. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. European Heart Journal. 2021;42(25):2439–54. DOI: 10.1093/eurheartj/ehab309